Synthetic Teriparatide exhibits distinct impurity profile with six unique deletion impurities compared to recombinant forms
Background
Teriparatide (TPT) is a crucial synthetic peptide primarily used in the clinical treatment of osteoporosis, an age-related bone disease characterized by reduced bone mass and increased fracture risk. While TPT reference materials are available from both synthetic and recombinant DNA origins for generic drug preparations, the presence of structurally related impurities can pose significant toxicological risks. Therefore, a systematic characterization of these impurity profiles from different synthetic sources is essential for robust regulatory evaluations of generic drugs' safety and efficacy, ensuring patient safety and consistent therapeutic outcomes.
Study Design
Researchers investigated the impurity profiles of Teriparatide using one commercially available chemical synthesis material and two recombinant synthesis pharmacopoeia reference standards. Structurally related impurities were separated via liquid chromatography, followed by mass spectrometry analysis using electro-spray ionization linear quadrupole ion trap-Orbitrap mass spectrometry (LC-HRMS). To ensure accurate quantification, an external standard method alongside four quantitative scenarios were employed to precisely measure the structurally related impurities present in the Teriparatide study materials.
Results
Distinct impurity profiles were observed across the Teriparatide study materials, varying significantly based on their synthetic origin. All three study materials, regardless of source, consistently contained one isomer and three oxidation impurities. However, a critical difference emerged: six amino acid deletion impurities were specifically observed and identified exclusively in the chemically synthetic Teriparatide material. These deletion impurities were absent in the recombinant counterparts. Furthermore, among all detected impurities, eight were newly characterized in this study, expanding the known impurity landscape for Teriparatide. This comprehensive characterization highlights the complexity of peptide drug manufacturing and the need for rigorous analytical methods. > Chemically synthetic Teriparatide uniquely contained six amino acid deletion impurities, absent in recombinant versions, underscoring source-dependent impurity profiles.
Key Findings
- Distinct impurity profiles were observed in Teriparatide materials from different synthetic sources.
- One isomer and three oxidation impurities co-existed in all synthetic and recombinant Teriparatide materials.
- Six amino acid deletion impurities were specifically identified in chemically synthetic Teriparatide material.
- Eight impurities were newly characterized in this study, expanding the known impurity landscape for Teriparatide.
Why It Matters
Ensuring the safety and efficacy of generic Teriparatide necessitates source-specific impurity monitoring during production and regulatory review. This research provides a robust LC-HRMS-based method for identifying and quantifying these critical impurities, which is vital for biohackers, clinicians, and manufacturers. For peptide users, understanding that synthetic Teriparatide can harbor distinct deletion impurities compared to recombinant forms is crucial for sourcing decisions. This impacts the regulatory evaluation of generic peptide drugs, potentially leading to more stringent quality control protocols and analytical requirements for different manufacturing pathways, ultimately enhancing patient safety and drug reliability.